CureVac N.V., a biotech company specializing in mRNA-based medicines, announced the resolution of its patent litigation with Pfizer and BioNTech regarding mRNA-based COVID-19 vaccines. Under the settlement, CureVac and its affiliate GSK will receive a total payment of $740 million, along with single-digit royalties on future U.S. sales of COVID-19 vaccines. Additionally, CureVac will receive $50 million from GSK by monetizing a portion of U.S. product royalties from a prior agreement. The settlement includes granting Pfizer and BioNTech a non-exclusive license to manufacture and sell mRNA-based COVID-19 and influenza products in the U.S., which will expand to a global license following BioNTech's acquisition of CureVac. This acquisition, announced earlier in June 2025, is set to proceed as planned, subject to regulatory approval.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。